Obstructive Sleep Apnea and Sodium Intake

What Is the Mechanism?

To the Editor:

We read with keen interest the study by Pimenta et al1 in a recent issue of CHEST (April 2013). These researchers enrolled 97 patients with resistant hypertension (RHTN) and screened them with overnight polysomnography for the presence of obstructive sleep apnea (OSA). In addition, 24-h urine sodium and aldosterone levels were measured. It was found that 77.3% of the patients with RHTN had OSA, which is much greater than the prevalence of OSA in the general population.2 On the other hand, 28.9% of the patients with RHTN were found to have hyperaldosteronism. It was found that the urinary sodium level was an independent marker for OSA severity in the patients with hyperaldosteronism (no such association was found in patients without hyperaldosteronism). We congratulate the authors, who contributed extensively to the topic of OSA and aldosterone metabolism. We would like to mention some of the possible mechanisms that may explain this association.

It is well known that patients with RHTN (including hyperaldosteronism), congestive heart failure, and advanced renal disease have a greater prevalence of OSA.3 Fluid overload associated with these conditions and rostral fluid shift may lead to narrowing of the upper airways, with resultant OSA. This hypothesis is bolstered by the fact that therapies aiming to remove excessive body fluid are associated with an improvement in OSA severity. Nevertheless, additional pathobiologic pathways may be implicated in the development or worsening of OSA severity. Research data point out that aldosterone may mediate multiple detrimental effects, such as tissue fibrosis, systemic inflammation, and oxidative stress.4 These mechanisms are believed to be responsible for an aldosterone-mediated increase in cardiovascular disease.4

REFERENCES


Cassie C. Kennedy, MD, FCCP Fabien Maldonado, MD, FCCP David A. Cook, MD, MHPE Rochester, MN

To the Editor:

We read with keen interest the study by Pimenta et al1 in a recent issue of CHEST (April 2013). These researchers enrolled 97 patients with resistant hypertension (RHTN) and screened them with overnight polysomnography for the presence of obstructive sleep apnea (OSA). In addition, 24-h urine sodium and aldosterone levels were measured. It was found that 77.3% of the patients with RHTN had OSA, which is much greater than the prevalence of OSA in the general population. On the other hand, 28.9% of the patients with RHTN were found to have hyperaldosteronism. It was found that the urinary sodium level was an independent marker for OSA severity in the patients with hyperaldosteronism (no such association was found in patients without hyperaldosteronism). We congratulate the authors, who contributed extensively to the topic of OSA and aldosterone metabolism. We would like to mention some of the possible mechanisms that may explain this association.

It is well known that patients with RHTN (including hyperaldosteronism), congestive heart failure, and advanced renal disease have a greater prevalence of OSA. Fluid overload associated with these conditions and rostral fluid shift may lead to narrowing of the upper airways, with resultant OSA. This hypothesis is bolstered by the fact that therapies aiming to remove excessive body fluid are associated with an improvement in OSA severity. Nevertheless, additional pathobiologic pathways may be implicated in the development or worsening of OSA severity. Research data point out that aldosterone may mediate multiple detrimental effects, such as tissue fibrosis, systemic inflammation, and oxidative stress. These mechanisms are believed to be responsible for an aldosterone-mediated increase in cardiovascular disease.
It is possible that aldosterone may mediate upper airways inflammation and fibrosis. This, in turn, may contribute to the detrimental effects of fluid overload in patients with OSA and hyperaldosteronism. However, to our knowledge, there are no studies investigating this potential mechanism. It will be important to study this hypothesis in future research, which should provide more basic knowledge on the pathophysiology of both OSA and aldosteronism.

Aibek E. Mirrakhimov, MD
Chicago, IL
Erkin M. Mirrakhimov, MD, PhD
Bishkek, Kyrgyzstan

Affiliations: From Saint Joseph Hospital (Dr A. E. Mirrakhimov); and Kyrgyz State Medical Academy (Dr E. M. Mirrakhimov).

Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Correspondence to: Aibek E. Mirrakhimov, MD, Saint Joseph Hospital, 2800 N Lake Shore Dr, Chicago, IL 60657; e-mail: amirrakhimov1@gmail.com

© 2013 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.

DOl: 10.1378/chest.13-0925

References


Response

We thank Drs Mirrakhimov and Mirrakhimov for their interest in our article1 and their comments. They point out that additional mechanisms other than fluid overload and rostral fluid shift may be associated with severity of obstructive sleep apnea (OSA) in patients with hyperaldosteronism and high dietary salt intake. Drs Mirrakhimov and Mirrakhimov are correct in hypothesizing that fibrosis and inflammation of the upper airway tissues may also contribute to the severity of OSA, although, as highlighted by them, there are no studies exploring this potential mechanism.

Experiments in animal models indicate that aldosterone excess, in addition to increasing BP, contributes directly to target-organ (heart, brain, and kidney) deterioration by inducing inflammation and perivascular fibrosis. These same studies have been consistent in demonstrating that the pressor, proinflammatory, and profibrotic effects of aldosterone are dependent on concomitant high dietary salt intake.

Clinical studies do suggest that aldosterone blockade reduces the severity of OSA. In a prospective, open-label study, 12 patients with resistant hypertension and moderate to severe OSA (apnea-hypopnea index ≥ 15) received spironolactone in addition to their previous antihypertensive medications for 8 weeks, after which overnight polysomnography was repeated. The apnea-hypopnea index was reduced by a mean of about 50% in all patients. This benefit occurred in the setting of increased diuresis, suggesting that aldosterone and sodium-mediated chronic fluid retention is an important mediator of OSA severity. This study is not able to distinguish diuretic vs antiinflammatory/fibrotic effect of mineralocorticoid blockade but does confirm aldosterone as an important mediator of OSA severity at least in patients with resistant hypertension.

In conclusion, we agree that additional mechanisms, other than fluid overload, may be involved in the development of OSA in these patients. Additional experimental and clinical studies are necessary to explore additional mechanisms involved in the development and maintenance of OSA in patients with resistant hypertension, hyperaldosteronism, or both to prospectively test management strategies of OSA.

Eduardo Pimenta, MD, PhD
Brisbane, QLD, Australia
David A. Calhoun, MD
Birmingham, AL

Affiliations: From the Endocrine Hypertension Research Centre and Clinical Centre of Research Excellence in Cardiovascular Disease and Metabolic Disorders (Dr Pimenta), The School of Medicine, The University of Queensland, Princess Alexandra and Greenslopes Private Hospitals; the Dante Fazzanese Institute of Cardiology (Dr Pimenta), São Paulo, Brazil; and the Sleep/Wake Disorders Center (Dr Calhoun), Division of Pulmonary, Allergy and Critical Care Medicine, and Vascular Biology and Hypertension Program (Dr Calhoun), The University of Alabama at Birmingham.

Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Funding/Support: This work was supported by National Institutes of Health National Center for Research Resources [Grant 5UL1 RR025777-04].

Correspondence to: David Calhoun, MD, The University of Alabama at Birmingham, 1530 3rd Ave S, Birmingham, AL, 35294-1150; e-mail: dccalhoun@uab.edu

© 2013 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.

DOI: 10.1378/chest.13-09069

Acknowledgments

Role of sponsors: The sponsors had no role in the design of the study; the collection and analysis of the data, or in the preparation of the manuscript.

References


